Citations

Showing 10 of 107964 citations.

An unbiased cell-culture selection yields DNA aptamers as novel senescent cell-specific reagents
Jachim, Sarah K. , Prieto, Luis I. , Dugan, Maria , Maher, L. James , Pearson, Keenan S, Doherty, Caroline D, Wilbanks, Brandon A, III, Louis James Maher , Pearson, Keenan , Doherty, Caroline Lloyd , Wilbanks, Brandon , Baker, Darren J. , LeBrasseur, Nathan K.

Mayo Clinic

No container title available | March 19, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1101/2025.03.19.643361 | PMID 40166138 Get It

ABSTRACT Cellular senescence is an irreversible form of cell-cycle arrest caused by excessive stress or damage. While various biomarkers of cellular senescence have been proposed, there are currently no universal, stand-alone indicators of this condition. The field largely relies on the combined detection of multiple biomarkers to differentiate senescent cells from non-senescent cells. Here we introduce a new approach: unbiased cell culture selections to identify senescent cell-specific folded DNA aptamers from vast libraries of trillions of random 80-mer DNAs. Senescent mouse adult fibroblasts and their non-senescent counterparts were employed for selection. We demonstrate aptamer specificity for senescent mouse cells in culture, identify a form of fibronectin as the molecular target of two selected aptamers, show increased aptamer staining in naturally aged mouse tissues, and demonstrate decreased aptamer staining when p16 expressing cells are removed in a transgenic INK-ATTAC mouse model. This work demonstrates the value of unbiased cell-based selections to identify new senescence-specific DNA reagents.
Systematic Review on Sustainable Design Thinking Through Biomimetic Approach
Edralin, Sabrina , Xu, Clark , Simasiku, Akebu, Priniotakis, Georgios , Alevizos, Vasileios , Gerolimos, Nikitas , Papakostas, George A. , Yue, Zongliang

Mayo Clinic

2025 International Conference on Artificial Intelligence in Information and Communication (ICAIIC) | March 19, 2025 | Volume: No volume available | Issue: No issue available | Pages: 0219-0223

10.1109/icaiic64266.2025.10920672 Get It

Whole-genome sequence of Potamopyrgus antipodarum —a model system for the maintenance of sexual reproduction—reveals a recent whole-genome duplication
Jalinsky, Joseph , McElroy, Kyle E. , Sharbrough, Joel , Fields, Peter D. , Higgins, Chelsea , Toll, Cynthia , Boore, Jeffrey L. , Logsdon, John M. , Neiman, Maurine , Bankers, Laura

Mayo Clinic

No container title available | March 19, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1101/2025.03.16.643514 Get It

Abstract Key unanswered questions in biology center on the causes, consequences, and maintenance of sexual reproduction (“sex”). Genome-driven processes are central to the evolutionary and genetic mechanisms inherent to sex, making genomic resources a fundamental part of answering these questions. We present the first genome assembly for a species that is uniquely well-suited for the study of (a)sex in nature, Potamopyrgus antipodarum . This New Zealand snail is unusual in featuring multiple separate transitions from obligately sexual to obligately asexual reproduction, leading to the coexistence of phenotypically similar sexual and asexual forms, a feature that is required to directly study the maintenance of sex. These separately derived asexual lineages constitute separate evolutionary experiments, providing a powerful means of characterizing how the absence of sex affects genome evolution. Our genome assembly provides critical steps towards understanding causes and consequences of sex in this system and important resources for the rapidly growing P. antipodarum and molluscan genomics research community. In characterizing this genome, we uncovered unexpected evidence for a recent whole-genome duplication (WGD) in P. antipodarum . This discovery sets the stage for using P . antipodarum to evaluate processes of rediploidization following WGD and assess whether WGD might drive transitions to asexuality.
Single-cell multiomics reveals disrupted glial gene regulatory programs in Alzheimer’s disease via interpretable machine learning
Zhang, Shuwen , Hu, Hongru , Wang, Xue , Chengjie, Xiong, Asmann, Yan W. , Ren, Yingxue , Zhang, Shuwen , Zhang, Shuwen

Mayo Clinic

No container title available | March 19, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1101/2025.03.14.643349 | PMID 40166228 Get It

ABSTRACT Recent development of single-cell technology across multiple omics platforms has provided new ways to obtain holistic views of cells to study disease pathobiology. Alzheimer’s disease (AD) is the most common form of dementia worldwide, yet the detailed understanding of its cellular and molecular mechanisms remains limited. In this study, we analyzed paired single-cell transcriptomic (scRNA-seq) and chromatin accessibility (scATAC-seq) data from the Seattle Alzheimer’s Disease Brain Cell Atlas (SEA-AD) Consortium to investigate the molecular mechanisms of AD at a cell-subpopulation-specific resolution focusing on glial cells. We benchmarked various multi-omics integration methods using diverse metrics and built an analytic workflow that enabled effective batch correction and cross-modality alignment, creating a unified cell state space. Through integrative analysis of 26 human brain samples, we uncovered AD-associated gene expression and pathway changes in glial subpopulations and highlighted important transcriptomic and epigenomic signatures via functional inference and interpretable machine learning paradigms, discovering the profound involvement of the Solute Carrier proteins (SLC) family genes in multiple glial cell types. We also identified glial cell-specific regulatory programs mediated by key transcription factors such as JUN and FOSL2 in astrocytes, the Zinc Finger (ZNF) family genes in microglia, and the SOX family of transcription factors in oligodendrocytes. Our study provides a comprehensive workflow and a high-resolution view of how glial regulatory programs are disrupted in AD. Our findings offer novel insights into disease-related changes in gene regulation and suggest potential targets for further research and therapy.
Chylous ascites as an initial presentation of lupus nephritis
Pogorelova, Mariya , Sungur, Can M, Sungur, Can M

Mayo Clinic

BMJ Case Reports | March 19, 2025 | Volume: 18 | Issue: 3 | Pages: e264415

10.1136/bcr-2024-264415 | PMID 40107757 Get It

We report the case of a man in his 50s who presented with pleural and pericardial effusions, chylous ascites, lymphadenopathy, weight loss and fatigue. Extensive evaluation ruled out malignancy, infection and many autoimmune conditions, but test results were positive for antinuclear antibodies and anti–double-stranded DNA antibodies. A kidney biopsy showed evidence of lupus nephritis (class 5). He ultimately was diagnosed with systemic lupus erythematosus and lupus nephritis. The patient began immunosuppressive treatment, and the manifestations started to resolve. Recognition of systemic lupus erythematosus as the cause of chylous ascites was essential for identifying effective therapy.
Risk Factor Number and Recurrence, Metastasis, and Disease-Related Death in Cutaneous Squamous Cell Carcinoma
Ran, Nina A., Granger, Emily , Brodland, David G., Cañueto, Javier , Carr, David R., Carter, Joi B., Hirotsu, Kelsey E. , Koyfman, Shlomo A. , Mangold, Aaron R. , Girardi, Fábio Muradás , Shahwan, Kathryn T. , Vidimos, Allison T. , Willenbrink, Tyler J., Wysong, Ashley, Ruiz, Emily S. , Mangold, A R , Granger, Emily E., Carucci, John A. , Srivastava, Divya , Wysong, Ashley

Mayo Clinic

JAMA Dermatology | March 19, 2025 | Volume: 161 | Issue: 6 | Pages: 597

10.1001/jamadermatol.2025.0128 | PMID 40105853 Get It

ImportanceCutaneous squamous cell carcinoma (CSCC) risk stratification is central to management, and physicians rely on tumor staging systems to estimate risk. The Brigham and Women’s Hospital (BWH) T staging system predicts risk based on 4 tumor risk factors (RFs). However, stage is not precisely associated with the number of RFs, as BWH stage T2b includes CSCCs with 2 and 3 RFs.ObjectiveTo determine how RF number is associated with the risk of recurrence, metastasis, and disease-related death.Design, Setting, and ParticipantsThis retrospective multination cohort study of CSCCs diagnosed between October 1, 1991, and July 19, 2023, was conducted at 12 centers in the US (10), Spain (1), and Brazil (1). Invasive CSCCs with confirmed negative margins longer than 14 days were included. Tumors were excluded if they were metastatic at presentation or received adjuvant therapy. Data were analyzed from October 2023 to August 2024.Interventions or ExposuresCSCCs were stratified by the number of the following RFs (0, 1, 2, 3, or 4): a diameter of 2 cm or larger, poorly differentiated histology, tumor extension beyond subcutaneous fat, and large caliber nerve invasion.Main Outcomes and MeasuresFive-year cumulative incidences of local recurrence, nodal metastasis, distant metastasis, and disease-specific death.ResultsA total of 16 844 CSCCs were included (5978 female individuals [35.5%]; median [IQR] age, 73.9 [65.7-81.8] years), with 0 (12 657 [75.1%]), 1 (2892 [17.2%]), 2 (1015 [6.0%]), 3 ( 225 [1.3%]) or 4 (55 [0.3%]) RFs. Median (IQ) follow up time was 33.6 (14.5-60.3) months. For local recurrence, the risk increased as the number of RF increased from 0 (1.7%; 95% CI, 1.5%-2.0%) to 1 (5.0%; 95% CI, 4.1%-5.9%) to 2 (8.8%; 95% CI, 7.0%-11.0%) to 3 (16.0%; 95% CI, 11.0%-22.0%) to 4 (33.0%; 95% CI, 19.0%-47.0%; P < .001 for between-group differences). This increase was also observed for nodal metastasis (0.6% [95% CI, 0.4%-0.7%] vs 3.6% [95% CI, 2.9%-4.4%] vs 11.0% [95% CI, 9.2%-13.0%] vs 20.0% [95% CI, 15.0%-26.0%] vs 28.0% [95% CI, 15.0%-42.0%], respectively; P < .001), distant metastasis (0.2% [95% CI, 0.1%-0.3%] vs 1.1% [95% CI, 0.7%-1.6%] vs 2.3% [95% CI, 1.4%-3.4%] vs 7.9% [95% CI, 4.6%-12.0%] vs 8.4% [95% CI, 2.6%-19.0%], respectively; P < .001), and disease-specific death (0.3% [95% CI, 0.2%-0.4%] vs 1.9% [95% CI, 1.4%-2.7%] vs 5.4% [95% CI, 4.0%-7.0%] vs 11.0% [95% CI, 6.7%-16.0%] vs 25% [95% CI, 12%-39%], respectively; P < .001). CSCCs with 3 RFs had higher cumulative incidences of local recurrence (1.6-fold), nodal metastasis (1.9-fold), distant metastasis (4.3-fold), and disease-specific death (1.9-fold) compared with those with 2 RFs.Conclusions and RelevanceThe results of this cohort study suggest that the number of RFs is an indicator of risk, and among BWH T2b tumors, those with 3 RFs represent a higher risk subset.
A Novel CREBBP/p300 Activator, YF2, Enhances Cytotoxic and Immune-Mediated Responses in B-Cell Lymphoma
Piorczynski, Ted B. , Estrella, Brian, Ricker, Edd C., Gonzalez, Yulissa, Obradovic, Aleksandar, Liu, Chang, Karan, Charles , Hwang, Howook, Camarillo, Jeannie M. , Abshiru, Nebiyu, Amengual, Jennifer E. , Piorczynski, Ted B , Kelleher, Neil L , Liu, Yuxuan , Ricker, Edd , Pazos, Manuel, Tolu, Seda , Tiger, Yun Kyoung , Obradovic, Aleksandar, Liu, Chang, Cremers, Serge , Nandakumar, Renu , Honig, Barry , Kelleher, Neil L.

Mayo Clinic

No container title available | March 19, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1101/2025.03.13.642871 | PMID 40161591 Get It

Abstract Germinal center B-cell lymphomas frequently exhibit monoallelic loss-of-function mutations in the histone acetyltransferases CREBBP and p300, which contribute to lymphoma development, disrupt normal germinal center biology, and promote immune evasion. This study evaluates YF2, a histone acetyltransferase activator that increases CREBBP/p300 activity, as a potential therapeutic approach for B-cell lymphoma. YF2 binds the bromodomain of CREBBP/p300, increasing their auto-acetylation and enzymatic activity. It also induces cytotoxicity in B-cell lymphoma cell lines, with a stronger response in those carrying CREBBP / EP300 mutations. Additionally, YF2 increases the acetylation of key CREBBP/p300 substrates, including H3K27, p53, and BCL6, leading to enhanced apoptosis and altered B-cell diTerentiation. YF2 is well tolerated in vivo and extends survival in both cell line- and patient-derived xenograft mouse models. Moreover, YF2 exposure upregulates antigen-presentation markers and reshapes the immune microenvironment, strengthening responses to immune checkpoint blockade. Taken together, these findings support pharmacologic activation of CREBBP/p300 with YF2 as a compelling therapeutic strategy for B-cell lymphoma. Significance YF2 stimulates CREBBP/p300 activity to normalize B-cell diTerentiation and enhance immune recognition, oTering a potential approach to limit lymphoma progression and strengthen immunotherapy responses.
Outcome of Goniotomy Over 120, 240 and 360 Degrees in Juvenile Open Angle Glaucoma: A Multicenter Study
Wang, Zhixuan , Fan, Hanying, Ge, Qingshu, Dang, Guangfu , Yang, Xiao , Xie, Lin , Zhu, Xiaoming , Yang, Yangfan , Wang, Yuhong , Liu, Jinkun , Zhang, Hongyang , Feng, Yuhan, Qi, Yongjun , Ye, Xiangxiang, Lai, Mingying , Lin, Peijie , Wang, Pusheng, Han, Shumei, Xu, Jiangang , Tao, Liming, Liu, Heting , Nie, Xin , Liao, Mengfei, Zou, Kai , Song, Yunhe , Lin, Fengbin , Xiaokaiti, Dilimulati, Liu, Xiaoyi , Fang, Zige , Jin, Ling, Chen, Yu , Han, Ying , Zeng, Liuzhi , Tham, Clement C, Yang, Zefeng , Ye, Xiangxiang, Lin, Peijie , Wang, Pusheng, Han, Shumei, Nie, Xin, Zou, Kai, Jiang, Yi , Zhou, Fengqi , Tham, Clement Chee Yung , Pan, Xiaojing , Weinreb, Robert Neal , Zhang, Xiulan

Mayo Clinic

Journal of Glaucoma | March 19, 2025 | Volume: 34 | Issue: 6 | Pages: 433-439

10.1097/ijg.0000000000002569 | PMID 40105411 Get It

Précis: 240-degree and 360-degree goniotomy (GT) demonstrated similar efficacy in intraocular pressure (IOP) reduction, both outperforming 120-degree GT in patients with juvenile open angle glaucoma (JOAG) at postoperative 6-month follow-up. Objective: To compare the surgical efficacy and safety of 120-degree, 240-degree, and 360-degree GT for patients with JOAG. Patients and Methods: This multicenter retrospective study included 102 eyes of 102 patients with JOAG, who underwent GT with a follow-up of at least 6 months. Patients were categorized into 3 groups: (1) 120-degree GT, (2) 240-degree GT, and (3) 360-degree GT. IOP, glaucoma medications, and complications were recorded at baseline and the final visit. Complete success and qualified success were defined as a postoperative IOP ≤21 mm Hg without and with medications, respectively. Results: Mean age of the participants was 24.4 ± 7.9 years. After a mean follow-up of 8.1 ± 2.7 months, complete success rates were similar between the 240-degree GT (45.2%) and the 360-degree GT (63.2%; P = 0.135), and both were superior to 120-degree GT (18.2%; P < 0.05). Qualified success rates among patients in the 120-degree, 240-degree, and 360-degree GT groups were 93.9%, 96.8%, and 100%, respectively, and showed no statistically significant difference (P = 0.292). 360-degree GT required fewer medications than 240-degree GT and 120-degree GT (P < 0.05), with no significant difference in medications between 120-degree GT and 240-degree GT (P > 0.05). Hyphema was the most common postoperative complication, with a significantly higher incidence in the 360-degree GT (68.4%) compared with the 240-degree GT (41.9%) and 120-degree GT (33.3%; P < 0.05). Conclusions: 240-degree and 360-degree GT showed similar efficacy in IOP reduction and were superior to 120-degree GT. More extensive GT may provide better outcomes in JOAG.
Population perspectives on benefits and harms of screening for metabolic dysfunction–associated steatotic liver disease
Allen, Alina M. , Kim, W. Ray , Canning, Rachel, Ou, Fang‐Shu , Benson, Joanne, Olson, Jessica L. , Venkatesh, Sudhakar K. , Li, Jiahui , Yin, Meng , Eslami, Maysa , Berg, Jonathon, Lazarus, Jeffrey V. , Canning, Rachel E. , Carrieri, Patrizia , Canning, Rachel , Ou, Fang-Shu , Venkatesh, Sudhakar K , Li, Jiahui , Eslami, Maysa , Ehman, Richard , Lazarus, Jeffrey V , Allen, Alina M , Yin, Meng , Carrieri, Patrizia , Benson, Joanne T., Ehman, Richard L.

Mayo Clinic

Hepatology | March 19, 2025 | Volume: 83 | Issue: 2 | Pages: 362-373

10.1097/hep.0000000000001311 | PMID 40105977 Get It

Background and Aims: Screening for diseases can have psychological impacts, such as anxiety, and requires acceptability from the population to be effective. This study examined the perspectives on the benefits and harms of screening for metabolic dysfunction–associated steatotic liver disease (MASLD) among the general population to optimize screening practices. Approach and Results: A survey was sent to participants enrolled between 2020 and 2024 in a prospective MASLD screening study in Olmsted County, MN. The survey assessed participants' perceived anxiety, stigma, quality of life, preferred screening methods, financial concerns, and lifestyle impacts following screening and diagnosis. Of the 461 participants, 342 (74%) completed the survey. Overall, 14% of participants reported screening-related anxiety, and 14% were concerned about disclosing a potential MASLD diagnosis to others. Among those without a MASLD diagnosis, 99% felt reassured about their liver health, 48% reported an improved quality of life, and 25% made lifestyle changes pertaining to their diet, alcohol use, and physical activity. Of the 77 participants diagnosed with MASLD, 52% experienced some anxiety about their new diagnosis; however, 95% and 97% considered it important to receive an early MASLD diagnosis to mitigate the risk for cirrhosis and cardiovascular disease, respectively. Notably, 79% of diagnosed participants found the diagnosis beneficial in adopting healthier habits, with 30% achieving a >10% weight loss after screening. Conclusion: This population-based survey demonstrates that the perceived benefits of proactive MASLD screening, such as increased awareness, lifestyle changes, and early diagnosis, outweigh the harms. These findings highlight the importance of early screening through patient-centered protocols to improve health outcomes.
Bone Appetit: Skellytour Sets the Table for Robust Skeletal Segmentation
Khosravi, Bardia , Rouzrokh, Pouria, Khosravi, Bardia

Mayo Clinic

Radiology: Artificial Intelligence | March 19, 2025 | Volume: 7 | Issue: 2 | Pages: No page available

10.1148/ryai.250057 | PMID 40105470 Get It